Yan Leyfman: Insights on Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X about a paper by Rachel E. Christensen et al. published in Clinical Lymphoma Myeloma and Leukemia:
“Global Derm Oncology Leader Dr. Shamir Geller and the Memorial Sloan Kettering Cancer Center team present new insights on mogamulizumab in mycosis fungoides (MF) and Sézary syndrome (SS).
In a retrospective study of 56 patients:
- 43% achieved skin response (median 2.3 mo)
- 90% achieved blood response (median 1.8 mo)
Skin response is strongest in:
- Patients with blood response (64%)
- High blood-stage disease (B2, 61%)
- Sézary syndrome (57%)
Even in patients without blood involvement, 24% had skin improvement – mainly erythrodermic cases.
Takeaway: Mogamulizumab shows promise for skin disease, particularly in advanced blood-stage MF/SS, but can also benefit select patients without blood involvement.”
Title: Skin Response to Mogamulizumab in Patients with Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort
Authors: Rachel E. Christensen, Robert Stuver, Stephen Dusza, Zachary D. Epstein-Peterson, Paola Ghione, Steven M. Horwitz, William Johnson, Alison J. Moskowitz, Patricia Myskowski, Melissa Pulitzer, Shamir Geller
You can read the Full Article on Clinical Lymphoma Myeloma and Leukemia.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023